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ABSTRACT 
Purpose  
The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of 
cancer patients stratified by four periods of time before death. 
Patients and methods  
Between 2008 and 2015, cancer patients were invited to participate in PROFILES(Patient Reported 
Outcomes Following Initial treatment and Long term Evaluation of Survivorship) registry studies. 
Patients were eligible for inclusion in this secondary analysis if they had been invited to complete the 
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire(EORTC 
QLQ-C30) in their last year of life(N=892). 458 patients (51%) responded. Descriptive statistics were 
used to describe the HRQoL of cancer patients in the last 3 months of life(N=61), last 3-6 
months(N=110), last 6-9 months(N=138), or last 9-12 months of their life(N=129) 
Results  
Patients in the last 3 months report a significant lower HRQoL, lower functioning and higher symptom 
burden of fatigue and appetite loss compared to patients in different time periods before 
death(p<0.008). Clinical relevance of the differences for global QoL, cognitive and social functioning 
were large. Patients' HRQoL in the last year of life was significantly lower than of the normative 
population (p<0,001). 
Conclusions  
All aspects of HRQoL are considerably impaired in patients with advanced cancer, with a marked 
lower HRQoL in the final months of life. This marked decline of HRQoL in the final months of life may 
be an indicator of approaching death and serve as an important trigger for end-of- life communication 
and decision-making about subsequent treatment and supportive care. 
 
Key words: quality of life, advanced cancer, palliative care, population-based cohort  
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INTRODUCTION 
Treatment of cancer is evolving rapidly and in recent decades cancer survival has improved partly 
attributed to screening (early detection) and better treatment [1]. Trends in the United States show that 
five year relative survival in adults with solid cancer has increased from 49% to 68% over the last 40 
years [2]. Nevertheless, despite these advances, cancer is still the second leading cause of death 
worldwide and more than 8 million people die of cancer every year [3]. Ergo, a large number of cancer 
patients experience a phase of their illness in which they might need palliative care. Palliative care 
aims to improve or maintain the quality of life (QoL) of patients and their relatives facing problems 
associated with a life-threatening disease, such as cancer. In their landmark paper, Temel et al 
showed that early palliative care in fact leads to significant improvements in both QoL and mood [4], 
as confirmed by a recent meta-analysis [5]. 
QoL is the perceived quality of an individual’s life, that is, an assessment of their well-being and 
includes multiple domains, including the physical, psychological, social, and spiritual domain. QoL is 
subjective and dynamic over time. Lynn and Anderson [6] have distinguished three common illness 
trajectories in patients potentially in need of palliative care, including the cancer trajectory. The 
‘cancer-trajectory’ consists of a short period of marked decline of function and a foreseen death. In line 
with this trajectory, several studies showed that cancer patients experience a steep decline of function 
and QoL in the last months of life. Giesinger et al [7] used routinely collected clinical practice data of 
85 advanced cancer patients and showed that during the last 3 months of life  HRQoL worsened 
sharply. Hwang et al [8] reported a fast deterioration in the last two months of life of 67 advanced 
cancer patients admitted to a US tertiary care teaching hospital. Furthermore, Elmqvist et al [9] 
combined data of two clinical trials from Norway and Sweden and showed that advanced patients’ 
functioning (n=116) deteriorated and the most marked changes occurred in the last 2 months of life.  
Insight in the course of advanced cancer patients’ quality of life (QoL) during the final year of life will 
serve to identify goals for timely interventions to improve patients’ QoL at the end-of-life. However, 
there are few population-based studies reporting the self-reported QoL of large groups of cancer 
patients  in their last months of life. Furthermore, previous studies reported on patients admitted to a 
single hospital who received medical care with palliative intent or on patients with limited expected 
survival who were included in a clinical trial regarding advanced palliative care, both potential subject 
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to selection bias. Moreover, clinical trial data does not reflect the daily practice. Population-based 
information about QoL during the final course of the disease for all cancer patients is lacking. 
Therefore, this study used data of a large population-based cohort  to assess health related quality of 
life (HRQoL) in the last year of life of advanced cancer patients stratified by four different periods of 
time before death. 
METHODS 
Study design and setting 
Data from the PROFILES (‘Patient Reported Outcomes Following Initial treatment and Long term 
Evaluation of Survivorship’) registry were used for secondary analyses. The PROFILES registry is an 
ongoing data collection of PROs within the sampling frame of the Netherlands Cancer Registry(NCR) 
and can be linked with clinical data of all individuals newly diagnosed with cancer in the Netherlands 
[10].  
 
Study population 
The current analysis included patients with cancer between May 2009 and October 2015 who received 
a questionnaire in their last year of life, using all study samples from the PROFILES registry. In all 
study samples, participants were included if they were older than 18 years at diagnosis and excluded if 
they were not able to complete a Dutch questionnaire according to their (ex-)attending specialist (i.e., 
cognitive impairment, non-native speaker, too ill to participate). Ethical approval was obtained for all 
study samples separately. 
 
Data collection 
A detailed description of the data-collection has been published previously [11]. In brief, in each study 
sample, cancer patients were informed about the study via a letter by their (ex-)attending specialist. 
This letter contained either an informed consent and a postal questionnaire, or a secured link to a 
web-based informed consent and online questionnaire. In study samples where the secured link was 
provided, the patient could return a postcard to request a paper-and-pencil questionnaire, if preferred. 
Data from the PROFILES registry are available for non-commercial scientific research, subject to 
study question, privacy and confidentiality restrictions, and registration[12]. 
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Study measures 
Sociodemographic and clinical data 
Socio-demographic and clinical data were obtained from the NCR. Socio-demographic variables 
included date of birth, gender, and socio-economic status (SES). SES was based on postal code of 
the residence area of the patient, combining aggregated individual fiscal data on the economic value 
of the home and household incomes, and was categorized into low, medium or high [13]. Questions 
on educational level and partnership were added to all questionnaire packages. Clinical data include 
cancer type, stage, and date of diagnosis. Cancer type was classified according to the third 
International Classification of Diseases for Oncology (ICDO-3) [14] and disease stage was classified 
according to TNM [15] or Ann Arbor Code (Hodgkin lymphoma and Non-Hodgkin lymphoma). TNM5 
was used for patients diagnosed from 2002 to 2003, TNM6 for patients diagnosed from 2003 to 2010, 
and TNM7 was used for patients diagnosed from 2010. Comorbidity was categorized according to the 
adapted Self-administered Comorbidity Questionnaire (SCQ). Patients were asked to report comorbid 
conditions present in the past 12 months. The total score was the sum of all positive responses (range 
0-14) and categorized into no comorbid condition, one comorbid condition, and at least two comorbid 
conditions [16]. Vital status and date of death were obtained from the Dutch municipal personal 
records database and was last verified on February 1st 2017. 
Quality of life 
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ-C30) (version 3.0) was used to assess HRQoL in cancer patients [17, 18]. It contains 
five functional scales on physical, role, cognitive, emotional and social functioning, an overall health 
status/global QoL scale, three symptom scales on fatigue, nausea and vomiting, and pain, and six 
single items. The scores were linearly transformed into a score between 0 and 100 [19]. A higher 
score for a functional scale indicates a higher level of functioning, but a higher score for a symptom 
scale represents a higher level of symptomatology. Furthermore, the recently developed QLQ-C30 
summary score has been used, because the sensitivity of the global QoL (ql) in advanced cancer 
patients seems limited, i.e. it seems not particularly well suited for detecting changes between patient 
groups [20]. This QLQ-C30 summary score was developed by Giesinger et al [21], with a higher score 
indicating a better HRQoL. 
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Normative population 
A reference cohort of 2,194 individuals from the general Dutch population (Center panel) was used to 
obtain the normative population. This reference cohort is representative for the Dutch speaking adult 
population in the Netherlands [22]. The normative population completed a questionnaire in November 
2013 that included the EORTC QLQ-C30, and items on socio-demographics. From this normative 
population, an age- and gender-matched selection (N=288) was made to compare HRQoL with the 
patient group. 
Statistical analysis 
Descriptive statistics were used to assess sociodemographic and clinical data and to determine the 
HRQoL in the last year of life of cancer patients. Respondents and non-respondents were compared 
using t-test (age) and Chi-square test (gender, partnership, SES). Four groups were created: patients 
who completed a questionnaire in their last 3 months of life (N=61), last 3-6 months (N=110), last 6-9 
months (N=138), and last 9-12 months (N=129). Differences between the four groups in HRQoL were 
analysed with a one-way ANOVA, followed by a Bonferroni post-hoc test. A Bonferroni correction was 
applied (P<0.008) ) to account for multiple testing. Additionally, clinical relevance of the differences 
was assessed using the meta-analysis of Cocks et al. [23], who published a guideline to aid 
interpretation of differences in EORTC QLQ-C30 scores defining thresholds for trivial, small, medium 
and large differences per subscale. A multivariable regression model was used to determine the 
associations between the EORTC QoL summary score and moment of completing the questionnaire 
(time before death in months as continuous variable), adjusted for gender, age, cancer type, and initial 
treatment.  
RESULTS 
A total of 892 patients received a questionnaire in their last year of life and 458 patients (51%) 
completed the questionnaire (mean age 72, standard deviation [SD] 9) (Table 1). Most common 
diagnoses were colorectal cancer (58%), lymphoma (22%), and gynaecological cancer (12%). Non-
respondents (n=434) were more often female and were more often in the last 3 months of life 
compared to respondents (p<0.05).  
[Table 1] 
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HRQoL in patients at the end of life 
Overall, the mean QLQ-C30 summary score of all patients in their last year of life was 73(SD 19), 
while in the last 3 months of life the mean QLQ-C30 summary score was 62(SD 22) (Table 2). Most 
severe symptom burden in the last year of life was found for fatigue (44(SD 30)) and dyspnoea (30(SD 
34)), while in the last 3 months fatigue 57(SD 29) and pain 39(SD 35) were most burdensome.  
HRQoL trajectory towards the end of life 
Significant differences of the QLQ-C30 summary score between different time periods before death 
were found (F(3,234) = 9.57, p = .000). HRQoL was statistically significantly lower in the last 3 months 
of life compared to the last 3-6 months (p=.0001), the last 6-9 months (p= .000), and the last 9-12 
months of life (p =.000) (Table 2 and Figure 1). All functioning subscales were significantly lower in the 
last 3 months of life, compared to patients in the previous time periods (p<0.008). Subscales global 
QoL, cognitive and social functioning showed a large clinically relevant mean lower score in patients in 
their last 3 months compared to patients in their last 9-12 months, respectively 17, 14 and 18 points. 
Physical and role functioning showed a medium clinically relevant lower score, respectively 19 and 23 
points. Differences of the symptoms fatigue and appetite loss between the last 3 months and the last 
9-12 months were also statistically significant. Fatigue, appetite loss, pain, insomnia, dyspnoea and 
nausea and vomiting showed medium clinically relevant differences between the last 3 months and the 
last 9-12 months of life (range 11-19 points).  
[Table 2] 
[Figure 1] 
HRQoL steeply declined in the last six months towards death; the QLQ-C30 summary score and the 
moment of completing the questionnaire (time before death in months) were statistically significant 
associated (β=2.3, 95% CI 0.23-4.33, p=.029).  
Normative population 
The QLQ-C30 summary score of advanced cancer patients was significantly lower in patients in their 
last year compared to the normative population, respectively 73 (SD 19) vs. 87 (SD 13), p <0.000 
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(Table 2). Overall, patients in their last year of life reported a lower functioning and a higher symptom 
burden on all subscales compared to the normative population.  
Discussion 
Advanced cancer patients experience a significantly impaired HRQoL in their last year of life, 
especially in the last three months of life. Patients also experience a high symptom burden, in 
particular regarding fatigue, dyspnoea and pain. HRQoL of cancer patients in their last year of life is 
worse compared to the normative population, particularly in the final phase of life.  
The marked lower QoL in the last 3 months of life is in line with the theoretical disease trajectory as 
described by Lynn and Adamson [6] and is in accordance with previous smaller studies [7-9]. A short 
period of evident decline is typical for cancer, as most patients with malignancies maintain a high level 
of functioning for a substantial period. However, once the cancer advances, the patient’s QoL sharply 
declines in the final weeks preceding death.  
Our analyses demonstrate that QoL measurement using patient-reported outcomes (PROs) is feasible 
in cancer patients in their last year of life. A response rate in the last year of life of 51% can be 
considered reasonable compared to the overall response rate of cancer patients in the Profiles registry 
(73-75%) [24-26]. As expected, we see a lower response rate among patients who participated in their 
last three months of life (36%). Completing a questionnaire in the final phase of life is obviously more 
difficult, possibly due to deterioration and higher symptom burden (as shown in this study). Using 
PROs in (early and late) palliative oncological care is important, as it provides valuable information 
about the QoL that would support end-of-life decision-making about subsequent treatment and 
supportive care. Furthermore, monitoring QoL and symptoms increases awareness among health care 
professionals to better anticipate on patients’ changing needs [27, 28]  and improves clinical outcomes 
(i.e. fewer ER visits, fewer hospitalizations, and better survival) [28].  
 
Strengths and limitations 
An important strength of the current analysis is the large population-based sample of cancer patients 
in their last year of life, including different primary cancer sites. Another strength is that, through 
linkage with cancer registry data and the Dutch municipal personal records database, we had access 
to complete and comprehensive data on socio-demographic and clinical characteristics, for the full 
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population of respondents and non-respondents. Furthermore, in our analysis we have used the 
EORTC QLQ-C30, a widely used instrument to measure HRQoL within oncology. However, many 
instruments to assess HRQoL of patients with advanced cancer are available [29]. The EORTC QLQ-
C30 seems suitable for patients with advanced cancer, although for patients in their final weeks of life 
the shortened version of this questionnaire, the EORTC QLQ-C15-PAL might be more appropriate 
[30]. A limitation of our study is its design, a cross-sectional analyses, based on a collection of 
separate study samples, with different inclusion criteria. 
Practical implications 
Our results clearly show a progressive deterioration in QoL towards the end of life. This marked 
decline of QoL may be an indicator of approaching death and therefore should be an important trigger 
for end-of-life communication and decision-making about subsequent treatment and care. Ideally, this 
should start earlier. However, timing of these end-of-life discussions remains challenging, “it always 
seems too early, until it’s too late”. Therefore, in current practice, a change in QoL or symptom burden 
can serve as a welcome starting point for these discussions to help professional caregivers to 
overcome the experienced barriers [31, 32]. The routine assessment of patient-reported outcomes 
(PROs) in advanced cancer patients helps to provide information on QoL and symptom burden and 
are widely recommended for clinical oncology practice [33] and for palliative care [34] . 
Conclusion 
Cancer patients experience a significantly impaired QoL and high symptom burden in their last year of 
life, especially in the last three months of life. This considerable decline of function and increase of 
symptom burden in the final months of life might serve as an indicator for end-of-life communication 
and supportive care.   
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Table 1 Sociodemographic and clinical characteristics 
 Respondents 
(N=458) 
Non respondents 
(N =434) 
 
p-value 
Normative populationa 
(N =288) 
     
Age (mean(SD); range min-max) 72(9); 40-96 73(11); 21-99 0.1985 71(11); 24-90 
Gender  (% male) 59% 49% 0.005* 54% 
Cancer type   0.000* n.a. 
Colon/rectum 58% (n=264) 48% (n=208)   
Lymphoma 22% (n=100) 15% (n=66)   
Gynaecological 12% (n=54) 20% (n=88)   
Prostate 6.1%(n=28) 9.5% (n=41)   
Other 2.6% (n=12) 7.1% (n=31)   
Metastasis at diagnosis   0.254 n.a. 
Yes 25% (n=114) 22% (n=94)   
No 75% (n=344) 78% (n=340)   
Time since diagnosis (yrs.) 
(mean(SD)) 
 
3.6(2.6) 
 
3.6(2.8) 
 
0.7915 
 
n.a. 
Up to two years 27% (n=125) 33% (n=141)   
2 – 4 years 40% (n=185) 34% (n=147)   
More than 4 years 32% (n=148) 34% (n=146)   
Moment of receiving questionnaire   0.000* n.a. 
Last 3 months of life 14% (n=65) 27% (n=118)   
3-12 months before death 86% (n=393) 73% (n=316)   
Comorbidity      
No comorbid condition 30% (n=126) -  23% (n=66) 
One comorbid condition 24% (n=110) -  26% (n=76) 
More than one comorbid conditions 48% (n=222) -  51% (n=146) 
Most frequent conditions     
Hypertension 34% (n=138) -  37% (n=107) 
Back pain 30% (n=116) -  35% (n=101) 
Arthritis 29% (n=113) -  33% (n=96) 
Heart disease 27% (n=109) -  24% (n=69) 
Diabetes mellitus 20% (n=80) -  11% (n=32) 
Pulmonary disease 17% (n=66) -  12% (n=35) 
Partnershipb     
Yes 74% (n=338) -  69% 
No 24% (n=110) -  31% 
14 
 
Social economic statusb     
High 23.6% (n=102) 23% (n=100)  - 
Intermediate 41.6% (n=180) 41.5% (n=180)  - 
Low 34.9% (n=151) 27.4% (n=119)  - 
Due to rounding off, percentages can exceed 100%  and an asterisk indicated statistically significance at p<0.01 
a Matched normative population on age and gender 
b Due to missings it does not add up to 458 (missings did not exceed 5%) 
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Table 2 Health related quality of life of cancer patients in their last months of life (n=458) 
 
I: Last 3 
months of 
life 
II: Last   3-6 
months of 
life 
III: Last  6-9 
months of 
life 
IV: Last  9-
12 
months of 
life 
 
 
Clinical 
relevance 
of mean 
difference 
between I 
and IV2 
 
Normative 
population 
 N =65 N =118 N =142 N =133  N =288 
 Mean (SD) Mean (SD) Mean (SD) Mean (SD) P-value1  Mean (SD) 
 
 
Summary score QoL 62 (22) 73 (19) 75 (18) 77 (17) 0.0000*  87 (13) 
        
Quality of life        
Physical functioning 48 (28) 63 (24) 62 25) 67 (25) 0.0000* medium 83 (19) 
Role functioning 39 (37) 59 (35) 57 (34) 62 (32) 0.0001* medium 83 (25) 
Emotional functioning 64 (26) 75 (25) 78 (23) 83 (20) 0.0000* - 87 (18) 
Cognitive functioning 68 (28) 80 (29) 76 (28) 82 (20) 0.0004* large 88 (17) 
Social functioning 60 (29) 74 (31) 72 (30) 78 (24) 0.0007* large 92 (18) 
Global quality of life 50 (27) 61 (24) 60 (24) 67 (20) 0.0000* large 75 (19) 
        
Symptoms        
Fatigue 57 (29) 44 (30) 42 (29) 38 (28) 0.0006* medium 23 (24) 
Nausea/vomiting 18 (24) 15 (25) 11 (22) 9.8 (20) 0.0536 medium 3 (11) 
Pain 39 (35) 28 (29) 27 (32) 25 (29) 0.0322 medium 22 (27) 
Dyspnoea 37 (38) 33 (34) 28 (34) 26 (32) 0.0758 medium 12 (22) 
Insomnia 37 (36) 30 (32) 26 (31) 22 (31) 0.0214 medium 19 (26) 
Appetite loss 36 (34) 25 (35) 18 (27) 17 (30) 0.0002* medium 5 (16) 
Constipation 21 (31) 12 (25) 14 (24) 12 (24) 0.0893 small 9 (18) 
Diarrhoea 22 (33) 11 (20) 13 (24) 19 (28) 0.0081 small 6 (14) 
1 A one-way ANOVA was conducted to determine if QoL differed for patients in different number of months before death, followed by 
post-hoc Bonferroni test (not shown).  
2 Indication of clinical relevance of mean differences, as reported by Cocks et al, 2010 
*statistically significant; a Bonferroni correction was applied (P<0.008)  ) to account for multiple testing. 
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Figure 1 Differences in HRQoL and its subscales in cancer patients in their last year of life (n=458) 
 
